Although the mean follow-up period (2.3 years) was of insufficient duration to be conclusive, there was no increased rate of death, new cancer, intracranial tumor recurrence, diabetes mellitus, or cardiovascular events in GH-treated patients compared with untreated patients. Here, GH1 is linked to cancer.